LUCID-201-001: A Double-Blind, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201

This double-blind, single-ascending dose trial (n=48) will assess the safety and tolerability of single ascending doses of orally administered Lucid-201 in healthy participants and patients with symptoms of depression on stable doses of SSRI or SNRI medications.

The study includes four cohorts of healthy volunteers and two cohorts of patients with mild-to-moderate depressive symptoms, who will receive either single ascending doses of Lucid-201 or 100 mg niacin. Safety and tolerability will be evaluated by monitoring common physical side effects, psychological assessments, vital signs, ECG, clinical laboratory tests, physical examination, concomitant medications, Columbia-Suicide Severity Rating Scale (C-SSRS), and HAM-D (for cohorts 5 and 6).

Topic Depression
Compound Psilocybin
Country Australia
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

FSD Pharma
FSD Pharma is a biopharmaceutical company established by Thomas Fairfull, Zeeshan Saeed, and Anthony Durkacz, with the company's name representing the first initial of each founder's last name.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.